University of Florida College of Medicine—Jacksonville emergency medicine researchers are working tirelessly to identify treatments for SARS-CoV-2, the virus behind the COVID-19 pandemic. These studies range from patient registries to various investigational pursuits.
UF Health’s Daniel Leveton recently reported on this important series of studies in Jacksonville, FL. The investigators here from UF now seek participants for these studies.
Two of these studies involve potential medications, including a randomized controlled study involving the administration of either losartan, an antihypertensive medication, or a placebo. This study emphasizes improvement in patients infected with SARS-CoV-2 experiencing respiratory failure.
Another study involves the Adaptive COVID-19 Treatment Trial 3 (ACTT-3), the multicenter trial conducted at about 100 sites nationwide. ACTT-3 is a randomized, double-blind placebo-controlled study investigating the combination of interferon beta-1a, an anti-inflammatory medication commonly used to treat multiple sclerosis, and remdesivir, the antiviral medication developed by Gilead, compared to remdesivir alone.
Abbott Laboratories sponsors yet another study investigating BinaxNOW, a rapid COVID-19 test. The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for this test. UF reports it’s UF Health Jacksonville campus was the first enrolling site in Florida testing BinaxNOW. Abbott submitted clinical trial data to the FDA that the BinaxNOW COVID-19 ag card evidenced sensitivity of 97.1% (positive percent agreement) and specificity of 98.5% (negative percent agreement) in COVID-19 suspected patients within the first seven days of symptom onset, reports Mr. Leveton of UF.
Another observational study was sponsored by the National Institute of Allergy and Infectious Diseases called Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC), UF, and two other Florida sites (Gainesville and Tampa) collect clinical data during a patient’s hospitalization and up to a year of associated data. This includes biological samples (e.g., blood, nasal swabs, and lung washings) for investigators to put together a comprehensive view of immune changes unfolding during a SARS-CoV-2 infection.
Finally, UF participates with an Indiana University COVID-19 Registry study enabling UF Health Jacksonville collaborative data sharing to benefit from COVID-19 patient containment and case escalation efforts. This registry was deemed a multicenter patient registry to aid hospitals nationwide to share mission-critical COVID-19 patient health data.
UF College of Medicine Senior Associate Dean POV
“UF Health emergency medicine is leading the way around COVID-19 research on our campus. They are providing key insights for the medical community at a time when we need answers,” said Alexander Parker, Ph.D., senior associate dean for research at the UF College of Medicine – Jacksonville. “As evidenced by the five studies underway in our emergency department, we are eager to contribute scientifically sound evidence regarding what are the best detection and treatment options for COVID-19 going forward.”
UF Health Jacksonville campus investigators include emergency physicians Lauren Black, MD, MPH; David Caro, MD; Elizabeth DeVos, MD, MPH; Faheem Guirgis, MD; Phyllis Hendry, MD; Ashley Norse, as well as the department of medicine physician Joseph Shiber, MD and infectious disease specialist Carmen Isache, MD.